| Primary |
| Transfusion |
28.6% |
| Acute Myeloid Leukaemia |
14.3% |
| Haemorrhage |
14.3% |
| Laparotomy |
14.3% |
| Postpartum Haemorrhage |
14.3% |
| Renal Failure Acute |
14.3% |
|
| Wrong Technique In Drug Usage Process |
18.2% |
| Apheresis |
9.1% |
| Contraindication To Medical Treatment |
9.1% |
| Melaena |
9.1% |
| No Adverse Event |
9.1% |
| Pyrexia |
9.1% |
| Rash Generalised |
9.1% |
| Respiratory Tract Infection |
9.1% |
| Transfusion Reaction |
9.1% |
| Transfusion-related Acute Lung Injury |
9.1% |
|
| Secondary |
| Pancytopenia |
23.4% |
| Drug Use For Unknown Indication |
14.6% |
| Product Used For Unknown Indication |
8.6% |
| Idiopathic Thrombocytopenic Purpura |
7.2% |
| Haemorrhagic Disorder |
5.7% |
| Acute Lymphocytic Leukaemia |
4.3% |
| Sedation |
4.3% |
| Prophylaxis |
3.8% |
| Maintenance Of Anaesthesia |
2.9% |
| Platelet Count Decreased |
2.9% |
| Thrombocytopenia |
2.9% |
| Acute Myeloid Leukaemia |
2.6% |
| Epistaxis |
2.4% |
| Allogenic Bone Marrow Transplantation Therapy |
2.1% |
| Aortic Dissection |
2.1% |
| Blood Product Transfusion |
2.1% |
| Thrombosis Prophylaxis |
2.1% |
| Transfusion |
2.1% |
| Induction Of Anaesthesia |
1.9% |
| Shock Haemorrhagic |
1.9% |
|
| Renal Failure Acute |
40.3% |
| Transfusion-related Acute Lung Injury |
6.7% |
| Anti-erythrocyte Antibody Positive |
5.9% |
| Haemoglobin Decreased |
5.9% |
| Hepatitis C |
4.2% |
| Hepatitis C Rna Positive |
4.2% |
| Sinus Bradycardia |
4.2% |
| Platelet Disorder |
3.4% |
| Htlv-1 Test Positive |
2.5% |
| Platelet Count Decreased |
2.5% |
| Tachycardia |
2.5% |
| Thrombocytopenia |
2.5% |
| Transfusion Reaction |
2.5% |
| Troponin Increased |
2.5% |
| Coombs Direct Test Positive |
1.7% |
| Haemorrhage Intracranial |
1.7% |
| Hepatitis Post Transfusion |
1.7% |
| Pancytopenia |
1.7% |
| Pulmonary Haemorrhage |
1.7% |
| Rash |
1.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
31.5% |
| Drug Use For Unknown Indication |
12.1% |
| Prophylaxis |
8.7% |
| Infection Prophylaxis |
5.4% |
| Coronary Artery Bypass |
5.2% |
| Aplastic Anaemia |
4.1% |
| Multiple Myeloma |
4.1% |
| Premedication |
3.6% |
| Acute Myeloid Leukaemia |
3.4% |
| Prophylaxis Against Graft Versus Host Disease |
2.9% |
| Myelodysplastic Syndrome |
2.3% |
| Idiopathic Thrombocytopenic Purpura |
2.2% |
| Aortic Valve Replacement |
2.1% |
| Thrombocytopenia |
2.1% |
| Bone Marrow Conditioning Regimen |
2.0% |
| Hypertension |
2.0% |
| Acute Lymphocytic Leukaemia |
1.7% |
| Nausea |
1.6% |
| Antifungal Prophylaxis |
1.6% |
| Pain |
1.4% |
|
| Injury |
8.8% |
| Pain |
8.6% |
| White Blood Cell Count Decreased |
8.4% |
| Sepsis |
8.3% |
| Unevaluable Event |
7.0% |
| Anxiety |
5.9% |
| Fear |
5.8% |
| Thrombocytopenia |
5.6% |
| Renal Failure |
5.2% |
| Anhedonia |
4.9% |
| Renal Impairment |
4.6% |
| Pneumonia |
3.7% |
| Emotional Distress |
3.5% |
| Death |
3.5% |
| Therapeutic Response Decreased |
3.3% |
| Renal Failure Acute |
2.9% |
| Stress |
2.7% |
| Pyrexia |
2.6% |
| Depression |
2.4% |
| Platelet Count Decreased |
2.4% |
|
| Interacting |
| Acute Myeloid Leukaemia |
60.0% |
| Hepatitis Chronic Active |
20.0% |
| Sarcoma |
20.0% |
|
| Respiratory Distress |
40.0% |
| Blood Creatine Increased |
20.0% |
| Dyspnoea |
20.0% |
| Tachycardia |
20.0% |
|
